Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHM 2101

Next Previous
Drug Profile

CHM 2101

Alternative Names: Cadherin 17 chimeric antigen receptor-positive (CAR) T cells; Cadherin-17; CDH17-CAR T; CHM-2101; CHM-2101 CAR-T cells

Latest Information Update: 05 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Chimeric Therapeutics; University of Pennsylvania
  • Class Antineoplastics; Antineoplastons; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Gastric cancer; Neuroendocrine tumours
  • Preclinical Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 May 2024 Phase-I/II clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)
  • 31 May 2024 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)
  • 31 May 2024 Phase-I/II clinical trials in Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top